

Global Contract Development and Manufacturing Organization (CDMO) Market: Analysis By Type (Chemical Drugs & Biologics), By Product (API/Bulk Drugs Drug Product Manufacturing (Inc. Dosage & Formulation Development) & Packaging), By Sourcing (In House & Outsourced), By Application (Oncology, Cardiovascular Disease, Diabetes, Hormonal, Glaucoma & Others), By Region, Size and Trends with Impact of COVID-19 and Forecast up to 2029

February 2024



Global Contract Development and Manufacturing Organization (CDMO) Market: Coverage

Executive Summary and Scope

Introduction/Market Overview

Global Market Analysis

Regional Market Analysis

Impact Of COVID-19

Dynamics

Competitive Landscape

Company Profiling

Global CDMO Market: Coverage

Scope of the Report

Attributes	Details
Title	Global Contract Development and Manufacturing Organization (CDMO) Market: Analysis By Type (Chemical Drugs & Biologics), By Product (API/Bulk Drugs Drug Product Manufacturing (Inc. Dosage & Formulation Development) & Packaging), By Sourcing (In House & Outsourced), By Application (Oncology, Cardiovascular Disease, Diabetes, Hormonal, Glaucoma & Others), By Region, Size and Trends with Impact of COVID-19 and Forecast up to 2029
Coverage	Global and Regional
Regional Coverage	North America, Europe, Asia Pacific, ROW
Market Influencing Variables	Growth Drivers, Challenges, Market Trends
Forecast Period of Market	2024-2029
Competition in the Market	Fragmented
Key Players	Catalent Pharma Solutions Inc., Samsung Biologics Co. Ltd., WuXi AppTec, Boehringer Ingelheim, WuXi Biologics (Cayman) Inc., Jubilant Pharmova Limited, Lonza Group AG, Siegfried Holding AG, Thermo Fisher Scientific Inc., FUJIFILM Holdings Corporation, Recipharm AB, Bushu Pharma and Piramal Group (Piramal Pharma Solutions)

Global CDMO Market

Executive Summary

Post-millennium, the biopharmaceutical sector has advanced significantly, witnessing the development of novel drugs and blockbuster medications. The "contract development manufacturing organization (CDMO)" model has emerged in response to growing demand. CDMOs, third-party providers, specialize in developing and manufacturing production processes for pharmaceutical firms, offering support throughout the drug-making journey. These entities, primarily focused on active pharmaceutical ingredient (API) manufacturing, have surged in the past decade due to mergers and acquisitions. While larger pharmaceuticals may opt for in-house capacities, smaller firms prefer CDMO outsourcing, reducing investment risks and providing access to specialized expertise. This trend enhances the efficiency and success of drug development endeavors. The global CDMO market was valued at US\$124.38 billion in 2023, and is expected to be worth US\$256.90 billion in 2029.


Global CDMO market can be classified on the basis of type, product, sourcing and application. The API/Bulk Drugs segment accounted for the highest share in the CDMO segment. This segment is witnessing significant growth due to the rising demand for both generic and innovative drugs globally. As APIs are an essential part of formulated pharmaceuticals, CDMOs, and CMO, have made major investments to increase their capacity for producing APIs in response to the rising demand for them. Factors such as the increasing prevalence of chronic diseases, the need for cost-effective pharmaceutical solutions, and the surge in outsourcing by pharmaceutical companies to streamline production processes are driving the growth of this segment.

The COVID-19 pandemic significantly impacted the contract development and manufacturing organization (CDMO) market. As the pharmaceutical industry raced to develop vaccines and treatments, CDMOs played a crucial role in providing manufacturing capabilities. Increased demand for vaccine production and the need for diversified supply chains elevated the importance of CDMOs. Additionally, the pandemic underscored the value of outsourcing for agility and risk mitigation in drug development. Despite challenges like supply chain disruptions, the CDMO market experienced growth, driven by accelerated research and development activities.

Global CDMO market is expected to show a significant increase during the forecasted period, i.e. from 2024 to 2029. The growth can be attributed to aging population, rising healthcare expenditure, rising prevalence of genetic disorders, increasing pharmaceutical R&D expenses, increasing demand for active pharmaceutical ingredient (API) and increasing outsourcing trends. However, some challenges are also impeding the growth of the market such as varying regulatory requirements across regions and dependence on patents, copyrights, trademarks and trade secrets.

CDMO Market: Global Analysis

Global CDMO Market by Value



CAGRs	
2019-2023	xx%
2024-2029	xx%

Global Contract Development and Manufacturing Organization (CDMO) market was valued at US\$... billion in 2023 and is anticipated to reach up to US\$... billion by 2029 from US\$... billion in 2024, with a CAGR of xx%.


CDMO Market: Global Analysis

Global CDMO Market by Type; 2023



Type	Share
Chemical Drugs	xx%
Biologics	xx%

Global CDMO Market by Sourcing; 2023



Sourcing	Share
In House	xx%
Outsourced	xx%


CDMO Market: Global Analysis

Global CDMO Market by Application; 2023



Application	Share
Oncology	xx%
Cardiovascular Disease	xx%
Diabetes	xx%
Hormonal	xx%
Glaucoma	xx%
Others	xx%


Global CDMO Market by Product; 2023



Product	Share
API/Bulk Drugs	xx%
Drug Product Manufacturing (Inc. Dosage & Formulation Development)	xx%
Packaging	xx%

CDMO Market: Global Analysis

Global CDMO Market by Region; 2023



Asia Pacific, xx%


North America, xx%

Europe, xx%


ROW, xx%

CDMO Market: Type Analysis

Global Chemical Drugs CDMO Market by Value




Global Biologics CDMO Market by Value




Type	CAGR (2024-2029)
Chemical Drugs	xx%
Biologics	xx%

CDMO Market: Product Analysis

Global API/Bulk Drugs CDMO Market by Value




Global Drug Product (Inc. Dosage & Formulation Development) Manufacturing CDMO Market by Value




Product	CAGR (2024-2029)
API/Bulk Drugs	xx%
Drug Product Manufacturing (Inc. Dosage & Formulation Development)	xx%
Packaging	xx%

CDMO Market: Sourcing Analysis

Global In House CDMO Market by Value




Global Outsourced CDMO Market by Value




Sourcing	CAGR (2024-2029)
In House	xx%
Outsourced	xx%

CDMO Market: Application Analysis

Global Oncology CDMO Market by Value




Global Cardiovascular Disease CDMO Market by Value




Application	CAGR (2024-2029)
Oncology	xx%
Cardiovascular Disease	xx%
Diabetes	xx%
Hormonal	xx%
Glaucoma	xx%
Others	xx%

CDMO Market: Regional Analysis

Asia Pacific CDMO Market by Value




North America CDMO Market by Value



Region	CAGR (2024-2029)
Asia Pacific	xx%
North America	xx%
Europe	xx%
ROW	xx%

Asia Pacific CDMO Market: An Analysis


Asia Pacific CDMO Market by Region; 2023



Region	Share (2023)	CAGR (2024-2029)
China	xx%	xx%
Japan	xx%	xx%
India	xx%	xx%
Rest of Asia Pacific	xx%	xx%

Asia Pacific CDMO Market: An Analysis


China CDMO Market by Type; 2023



Type	Share (2023)	CAGR (2024-2029)
Chemical Drugs	xx%	xx%
Biologics	xx%	xx%

North America CDMO Market: An Analysis


North America CDMO Market by Region; 2023



Region	Share (2023)	CAGR (2024-2029)
The US	xx%	xx%
Canada	xx%	xx%
Mexico	xx%	xx%

North America CDMO Market: An Analysis


The US CDMO Market by Product; 2023



Product	Share (2023)	CAGR (2024-2029)
API/Bulk Drugs	xx%	xx%
Drug Product Manufacturing (Inc. Dosage & Formulation Development)	xx%	xx%
Packaging	xx%	xx%


Europe CDMO Market: An Analysis

Europe CDMO Market by Region; 2023



Region	Share (2023)	CAGR (2024-2029)
Germany	xx%	xx%
UK	xx%	xx%
France	xx%	xx%
Rest of Europe	xx%	xx%

Global CDMO Market: Dynamics



Global CDMO Market: Competitive Landscape

Players Profiled

- ❑ Catalent Pharma Solutions Inc.
- ❑ Samsung Biologics Co. Ltd.
- ❑ WuXi AppTec
- ❑ Boehringer Ingelheim
- ❑ WuXi Biologics (Cayman) Inc.
- ❑ Jubilant Pharmova Limited
- ❑ Lonza Group AG
- ❑ Siegfried Holding AG
- ❑ Thermo Fisher Scientific Inc.
- ❑ FUJIFILM Holdings
- ❑ Recipharm AB
- ❑ Bushu Pharma
- ❑ Piramal Group (Piramal Pharma Solutions)

Global Biologics CDMO Players by Market Share; 2023 (Percentage,%)

